Nalorphine
Sign in to saveNalorphine (; also known as '''N-allylnormorphine; brand names Lethidrone and Nalline''') is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.
Research
1,348 papers- Pharmacological characterization of nalorphine, a kappa 3 analgesic.The Journal of pharmacology and experimental therapeutics · 1991
- Nalorphine in opiate poisoning.British medical journal · 1969
- [Nalorphine; a summary].Die Pharmazie · 1956
- Letter: Neonatal-strength ampoules of nalorphine.British medical journal · 1976
- ON ANTIDOTES.British journal of anaesthesia · 1954
via PubMed
Article
7 sectionsContents
- Pharmacology
- Pharmacodynamics
- Chemistry
- Analogues
- Synthesis
- See also
- References
Nalorphine (; also known as '''N-allylnormorphine; brand names Lethidrone and Nalline') is a mixed opioid agonist–antagonist with opioid antagonist and analgesic properties. It was introduced in 1954 and was used as an antidote to reverse opioid overdose and in a challenge test to determine opioid dependence.
Nalorphine was the second opioid antagonist to be introduced, preceded by nalodeine (N''-allylnorcodeine) in 1915 and followed by naloxone in 1960 and naltrexone in 1963. Due to potent activation of the κ-opioid receptor, nalorphine produces side effects such as dysphoria, anxiety, confusion, and hallucinations, and for this reason, is no longer used medically.